Stocks and InvestingStocks and Investing
Fri, December 2, 2022
Thu, December 1, 2022
Wed, November 30, 2022
Tue, November 29, 2022

Andrew Galler Maintained (ARWR) at Hold with Decreased Target to $37 on, Nov 29th, 2022


Published on 2024-10-28 00:21:45 - WOPRAI, Andrew Galler
  Print publication without navigation


Andrew Galler of Morgan Stanley, Maintained "Arrowhead Pharmaceuticals, Inc." (ARWR) at Hold with Decreased Target from $41 to $37 on, Nov 29th, 2022.

Andrew has made no other calls on ARWR in the last 4 months.



There are 2 other peers that have a rating on ARWR. Out of the 2 peers that are also analyzing ARWR, 0 agree with Andrew's Rating of Hold.



These are the ratings of the 2 analyists that currently disagree with Andrew


  • Edward Tenthoff of "Piper Sandler" Maintained at Buy with Decreased Target to $64 on, Thursday, November 10th, 2022
  • Madhu Kumar of "Goldman Sachs" Maintained at Strong Buy with Increased Target to $65 on, Monday, August 8th, 2022